ARTICLE | Deals
Pfizer sees potential best-in-class CD47s in $2.3B Trillium takeout
In high-premium deal, Pfizer gains fusion proteins for blood cancers
August 23, 2021 10:47 PM UTC
In its buyout of Trillium valuing the biotech at $2.3 billion, Pfizer gains a pair of therapies it believes could be best-in-class CD47 inhibitors for hematological malignancies and backbones for combinations, including a pairing with a bispecific for multiple myeloma.
Pfizer Inc. (NYSE:PFE) will pay $18.50 per share for Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL), representing a 204% premium over the biotech’s close Friday at $6.09. Trillium had touched an intraday 52-week low of $5.80 during Friday’s session...